Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. - Wikidata - awgldk - TriplyDB

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

http://www.wikidata.org/entity/Q34144814

about

Light chain (AL) amyloidosis: update on diagnosis and management The Prevalence and Management of Systemic Amyloidosis in Western Countries Historical and Current Concepts of Fibrillogenesis and In vivo Amyloidogenesis: Implications of Amyloid Tissue Targeting Secondary amyloidosis in autoinflammatory diseases and the role of inflammation in renal damage Update on treatment of light chain amyloidosis Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs Amyloid diseases of the heart: current and future therapies Interaction of serum amyloid P component with hexanoyl bis(D-proline) (CPHPC)Stop chronic kidney disease progression: Time is approaching Evolving landscape in the management of transthyretin amyloidosis Pentraxins: structure, function, and role in inflammation The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use.Phagocyte depletion inhibits AA amyloid accumulation in AEF-induced huIL-6 transgenic mice The influence of delivery vectors on HIV vaccine efficacy Novel drugs targeting transthyretin amyloidosis.FAP neuropathy and emerging treatments.Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy.An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis.Mass spectrometry analysis reveals non-mutated apolipoprotein A1 lumbosacral radiculoplexus amyloidoma.A human monoclonal IgG that binds aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo.AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils.Noncerebral Amyloidoses: Aspects on Seeding, Cross-Seeding, and Transmission.Inhibition of TTR aggregation-induced cell death--a new role for serum amyloid P component.Recent advances in transthyretin amyloidosis therapy (18)F-FDG PET/CT in Patients with Nodular Pulmonary Amyloidosis: Case Report and Literature Review.Depletion of spleen macrophages delays AA amyloid development: a study performed in the rapid mouse model of AA amyloidosis Amyloidosis: pathogenesis and new therapeutic options.Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis Current perspectives on cardiac amyloidosis.IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA.Autoinflammation in 2010: expanding clinical spectrum and broadening therapeutic horizons Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model.Leukocyte Cell-Derived Chemotaxin 2-Associated Amyloidosis: A Recently Recognized Disease with Distinct Clinicopathologic Characteristics C1q ablation exacerbates amyloid deposition: A study in a transgenic mouse model of ATTRV30M amyloid neuropathy.Updates in cardiac amyloidosis: a review.Al amyloidosis Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France Recent advances in the treatment of familial amyloid polyneuropathy.Pathogenetic mechanisms of amyloid A amyloidosis.

P2860

Q21198863-82811F5D-D58B-4A69-A097-33128BF68BAA Q26740436-88D44DFF-7407-4B10-A65C-E16FF2A999E9 Q26744469-968C04CE-CB95-45D5-840A-C1F6F5E8F18E Q26770744-9066DFF0-FE14-4927-BF96-4597CC8B5A18 Q26829735-AB86AE14-17D3-4FAF-B034-492DDDB5322E Q27009309-D326AC1C-D02F-4B48-A890-8038EACB7E5E Q27023836-96D47F65-E90F-42F1-AF92-58D5572CA4FF Q27684907-9F96E475-5066-496C-8368-49470E7C8085 Q28078020-1DECB4E3-6A70-4342-900F-E20FF1A47F42 Q28086773-E3C55A28-2B0F-435B-9EDD-BFFC106D0830 Q28676262-8BB7CE4B-22F1-42AD-81F4-726568BE68BD Q33632041-77D05C94-F2CF-4A8E-BF84-3AD8D4CF06F5 Q33796862-204B40DD-4B18-474A-86F7-BEA1F274366A Q33955053-63747347-23F3-4B12-AD81-8FD2976A8DA9 Q34077543-89BED3BF-BEBD-4D5F-88EE-E8217D711DCD Q34400138-EFAAA054-5B2A-4495-8383-886ED7CF41C4 Q34401190-5F540E59-DEE0-4F76-82A3-6639BB4D83A7 Q34422510-6400AF7B-4CA9-4F00-9A85-D0D624906E7E Q34428314-94498915-FFA0-443A-A34B-46AE493CFD09 Q34440462-843FC3A9-5726-4F2B-9CE4-453F54E3433A Q34473306-79F83B51-1D41-4A3A-A321-274AFE8EB773 Q34541038-C61B9AA4-6495-47E3-B9BD-162B5A975846 Q34549794-78F401F3-9CB4-44F2-A71F-0DC7F74FE813 Q34580145-2E570757-CA1F-4E03-B30C-965A9613D4A5 Q34664696-409CA85B-D8E8-495D-A250-95F0E21FB415 Q34792078-1489F045-3C01-494A-87B0-6691C515C4DE Q35043703-4BE8AB60-49B1-4F4B-9C46-B7BE45BC88F9 Q35111771-054DA9DC-18E8-4649-9242-7899E0D4EDBB Q35179540-99467E79-468F-4F11-BB35-707896F83FF0 Q35964900-2B3A9064-2868-42B9-A821-93704204288A Q35992493-ECE18FDE-6E05-4D00-A049-C4E5CA212111 Q36087406-2B161739-1B92-4C99-8C31-706C9EBBD3FA Q36185908-AAD8C474-D83B-42D0-B002-068F23B51D86 Q36250353-A25B6970-E446-4954-91FB-D105DDB92956 Q36346078-A76D1CDD-E342-413A-9AF6-A06B75B9E858 Q36366356-7F85AA4C-FBAF-4E08-9D7D-62AC4DCD877D Q36392233-ADED59E6-0D66-4900-AAE8-B32450CDB044 Q36536822-E7438D43-AAEC-4B8E-8575-0A3B848619A2 Q36638665-8A19BCA4-16B9-426B-A3EB-F2092150D560 Q37218553-7384D22B-BF22-47BA-8767-5868FDE823DB

P2860

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

http://www.wikidata.org/entity/Q34144814

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

@ast

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

@en

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

@nl

type

label

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

@ast

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

@en

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

@nl

prefLabel

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

@ast

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

@en

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

@nl

P1433

Q34144814-53DDAF76-B26C-459D-AA3B-1E724271311E

P1476

Q34144814-AACF9847-E45C-4F87-8465-8D6451317D31

P2093

Q34144814-05A31DEC-FE24-4C5D-848B-AAC47A5F9070

Q34144814-0B6E02A5-107C-40B9-AFAC-47704E3A26EF

Q34144814-451AF527-F542-4DE7-848B-E707343EF41B

Q34144814-4B35261A-3CD2-41D2-A6B6-BDA1CCE6CB6D

Q34144814-51C295C5-B269-49F5-8617-769A1E22C870

Q34144814-575E4C0F-E588-4E47-AE15-A383F6524715

Q34144814-66AB1351-2EB8-4998-AF24-5FBEF1D6BD55

Q34144814-7AC3CCDF-5460-499C-95B1-C9554A0F935C

Q34144814-832F5815-C16C-4405-8C80-713FAEF57E0B

Q34144814-85E02B39-A9D1-463E-B040-D5356D670A3C

P2860

Q34144814-009ED3B9-100B-4059-B291-CD28B8C4B9AE

Q34144814-052A6A70-20DC-415A-81C4-21FFD5213EF5

Q34144814-12B4E918-4ADC-45E1-B83B-C071B446B694

Q34144814-1A9E3141-3431-4D62-9F7D-62A7AE45D31C

Q34144814-1B033F57-BE7A-48A4-BB9A-002B26431CFE

Q34144814-1E757541-EB7A-48E2-A48A-26DB957ADB97

Q34144814-5B69E0E9-D9B4-4842-84C8-FA61580CCBDD

Q34144814-6312E3BB-7FBE-4983-931C-0F713A06514B

Q34144814-75251CDA-5514-4A62-A979-03DDAF2A3BF3

Q34144814-7A093D11-2601-4E0B-B2B6-7DCCDDC6E90F

P2888

Q34144814-D6D78EDD-9A3C-4B4C-9672-029A368FFB70

P304

Q34144814-11A1F881-ED01-480C-8629-851DAB26C852

P31

Q34144814-D4A359A6-C5A9-451A-9CD7-A862D16BE0B1

P356

Q34144814-97362E9E-AA5F-4493-B241-8105C6655ED9

P407

Q34144814-40199FE0-8218-4576-A5BB-8420DE18CBF2

P433

Q34144814-A35AD604-52C3-45E5-BA8F-AB64267C663D

P478

Q34144814-1176A1C6-34B4-4ED8-B41E-982CAD6563BE

P50

Q34144814-23C2A39F-0A07-48B4-9D46-F269F763486D

Q34144814-40EA9550-AC0C-4DED-A5B9-5D2D936A5E9C

Q34144814-AE26F818-9BC7-4541-AE6F-B016376793FE

P577

Q34144814-D8A0BB57-6D4E-429A-B53B-8578CE476B0C

P5875

Q34144814-720E28F0-FA7D-4C1D-AF9A-35DEBD4065A2

P6179

Q34144814-48E32865-0A3D-4A67-BBCB-1C1DA31FE79E

P698

Q34144814-A48F142C-423F-46A6-A6DB-5110DD94C24A

P921

Q34144814-197A2B6A-10EB-4CD1-94F6-6EF87F2EEB7C

P932

Q34144814-3895C881-F567-4025-8F77-EBD9FAF7A45F

P356

P1433

P1476

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

@en

P2093

Amar P Dhillon

http://www.w3.org/2001/XMLSchema#string

Andrzej Loesch

http://www.w3.org/2001/XMLSchema#string

Aviva Petrie

http://www.w3.org/2001/XMLSchema#string

David J Millar

http://www.w3.org/2001/XMLSchema#string

Glenys A Tennent

http://www.w3.org/2001/XMLSchema#string

Graham W Taylor

http://www.w3.org/2001/XMLSchema#string

J Ruth Gallimore

http://www.w3.org/2001/XMLSchema#string

Janet A Gilbertson

http://www.w3.org/2001/XMLSchema#string

Julian D Gillmore

http://www.w3.org/2001/XMLSchema#string

Karl Bodin

http://www.w3.org/2001/XMLSchema#string

P2860

Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis

Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene

Binding of serum amyloid P-component (SAP) by amyloid fibrils

Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity.

Radioimmunodetection of amyloid deposits in patients with AL amyloidosis.

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.

Natural history and outcome in systemic AA amyloidosis.

Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies.

Amyloid nephropathy of Ostertag with special reference to renal glomerular giant cells.

P2888

P304

93-97

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE09494

http://www.w3.org/2001/XMLSchema#string

P407

P433

7320

http://www.w3.org/2001/XMLSchema#string

P478

468

http://www.w3.org/2001/XMLSchema#string

P50

Arthur R Bradwell

P577

2010-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47510490

http://www.w3.org/2001/XMLSchema#string

P6179

1000282514

http://www.w3.org/2001/XMLSchema#string

P698

20962779

http://www.w3.org/2001/XMLSchema#string

P921

P932

2975378

http://www.w3.org/2001/XMLSchema#string